Talaporfin
Appearance
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C38H41N5O9 |
Molar mass | 711.772 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a chlorin based photosensitizer used in photodynamic therapy (PDT).
It absorbs red light at 664-667 nm normally provided by a laser tuned to this wavelength.[1]
It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.[2]
References
- ^ Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, Suga Y, Honda H, Nagatsuka Y, Ohira T, Tsuboi M, Hirano T (June 2006). "Photodynamic therapy (PDT) for lung cancers". Journal of Thoracic Oncology. 1 (5): 489–93. doi:10.1016/S1556-0864(15)31616-6. PMID 17409904.
- ^ Usuda J, Kato H, Okunaka T, Furukawa K, Honda H, Suga Y, Hirata T, Ohira T, Tsuboi M, Hirano T (June 2006). "Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer". Journal of Clinical Oncology. 24 (18 suppl): 7229. doi:10.1200/jco.2006.24.18_suppl.7229.
Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells